Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Novel Anticoagulants and the Reduction of Stroke in Individuals with Atrial Fibrillation
FY 2015-16
Summary
Individuals with atrial fibrillation (AF) have a five-fold increased risk of ischemic stroke. Consequently, AF patients are treated with anticoagulants such as vitamin K antagonists (VKA), which reduce the incidence of stroke by approximately 60% compared to placebo. However, VKA areassociated with a significant increase inbleeding complications and require regular monitoring due to theirnarrow therapeutic window. Novel oral anticoagulants (NOAC) are a new andattractive alternative to VKA for the treatment of AF. NOAC are substantially easier to use because they do not require routine blood tests and monitoring, which is impractical for many AF patients on VKA.Randomized controlled trials have shown that the efficacy of NOAC in preventing ischemic stroke is comparable to, if not better thanthat of VKA. As compared to VKA, NOAC have also been shown toreduce the risk of certainside effects including hemorrhage and death. However, clinical trials are conducted in well-defined clinical settings, and are also highly selective, excluding many vulnerable and at-risk subgroups of AF patients, such as those with a recent history of major stroke, or the elderly above age 75. Therefore, theoutcomes of using NOACin everyday clinical practice remain unclear. This project will use an observational study design to investigative the effectiveness and side effects of NOAC in the generalpopulation and under standard conditions. This willhelp to identify the profiles of AF patients who would most benefit from using NOAC as opposed to VKA, information whichcan then be used by clinicians to determine the best course of treatment for each of their individual patients.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
350142
Name
Loo Simone
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel Anticoagulants and the Reduction of Stroke in Individuals with Atrial Fibrillation
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Atrial Fibrillation; Hemorrhage; Ischemic Stroke; Novel Oral Anticoagulants; Observational Studies; Systemic Embolism; Vitamin K Antagonists
Abstract
Individuals with atrial fibrillation (AF) have a five-fold increased risk of ischemic stroke. Consequently, AF patients are treated with anticoagulants such as vitamin K antagonists (VKA), which reduce the incidence of stroke by approximately 60% compared to placebo. However, VKA areassociated with a significant increase inbleeding complications and require regular monitoring due to theirnarrow therapeutic window. Novel oral anticoagulants (NOAC) are a new andattractive alternative to VKA for the treatment of AF. NOAC are substantially easier to use because they do not require routine blood tests and monitoring, which is impractical for many AF patients on VKA.Randomized controlled trials have shown that the efficacy of NOAC in preventing ischemic stroke is comparable to, if not better thanthat of VKA. As compared to VKA, NOAC have also been shown toreduce the risk of certainside effects including hemorrhage and death. However, clinical trials are conducted in well-defined clinical settings, and are also highly selective, excluding many vulnerable and at-risk subgroups of AF patients, such as those with a recent history of major stroke, or the elderly above age 75. Therefore, theoutcomes of using NOACin everyday clinical practice remain unclear. This project will use an observational study design to investigative the effectiveness and side effects of NOAC in the generalpopulation and under standard conditions. This willhelp to identify the profiles of AF patients who would most benefit from using NOAC as opposed to VKA, information whichcan then be used by clinicians to determine the best course of treatment for each of their individual patients.
Competitiondate
201512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Loo, Simone
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~